CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2012;36(4):262-267.   Published online August 20, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.4.262

Excel Download

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Diabetes & Metabolism Journal. 2012;36(4):262   Crossref logo
Link1 Link2 Link3

HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Journal of Hepatology. 2020;73:S124   Crossref logo
Link1 Link2

Treatment of non-alcoholic fatty liver disease
Journal of Gastroenterology and Hepatology. 2002;17:S385-S388   Crossref logo
Link1 Link2 Link3

Non-alcoholic fatty liver disease
Journal of Gastroenterology and Hepatology. 2002;17:S186-S190   Crossref logo
Link1 Link2 Link3

Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review
Archives of Hepatitis Research. 2017;3(1):029-036   Crossref logo
Link1

Non-alcoholic fatty liver disease
Journal of Diabetes. 2012;4(3):266-280   Crossref logo
Link1 Link2

Non-alcoholic fatty liver disease
Alimentary Pharmacology & Therapeutics. 2003;17(8):977-986   Crossref logo
Link1 Link2 Link3

Clinicopathological features of non-alcoholic fatty liver disease
Hepatology Research. 2011;41(10):911-920   Crossref logo
Link1

Treatment of non-alcoholic fatty liver disease
Journal of Gastroenterology and Hepatology. 2013;28:79-80   Crossref logo
Link1 Link2 Link3

Su1498 - A Highly Selective and Potent Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity (NAS) in two Murine Models of Non-Alcoholic Steatohepatitis (NASH)
Gastroenterology. 2018;154(6):S-1159   Crossref logo
Link1 Link2